Poster Discussion Session Quality of Life (Qol) with Ribociclib (Rib) plus Aromatase Inhibitor (Ai) Versus Abemaciclib (Abe) plus Ai as First-Line (1L) Treatment (Tx) of Hormone Receptor-Positive/ Human Epidermal Growth Factor Receptor-Negative (Hr+/Her2-) Advanced Breast Cancer (Abc), Assessed via Matching-Adjusted Indirect Comparison (Maic).